Canadian Manufacturing

MilliporeSigma announces opening of commercial facility in France

by CM Staff   

Exporting & Importing Financing Manufacturing Operations Sales & Marketing Supply Chain Manufacturing marketing medical manufacturing Pharmaceutical Manufacturing sales


The Martillac facility reportedly features two 2000-liter bioreactors in one manufacturing suite to increase capacity and flexibility.

MilliporeSigma’s new commercial facility for its Millipore® CTDMO Services offering at the company’s site in Martillac, France. MilliporeSigma is the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany.

BURLINGTON — MilliporeSigma, the U.S. and Canadian pharmaceutical manufacturing business of Merck KGaA, Darmstadt, Germany, announced that its Life Science business sector has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France. The 2,700-square-meter facility will try and provide a global supply of commercial drug substances, including mAbs and other recombinant proteins, from an integrated site featuring single-use equipment and onsite regulatory, quality and technical people.

“Our clients are pioneering modern medicine and managing multiple partners, supply chain needs and complex priorities and are turning to our company to help them navigate the complexity and provide flexibility and scale,” said Dirk Lange, Head of Life Science Services, Life Science business sector of Merck KGaA, Darmstadt, Germany. “With this facility and our global Millipore® CTDMO Services network, we offer truly differentiated services, including templates for drug development, manufacturing and commercialization to accelerate molecules to market with one experienced partner.”

This expansion will support clients such as Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focusing on pediatric immunotherapies leveraging the company’s CTDMO services. “With the Life Science business sector’s support, we’ve brought our product candidate for pediatric brain cancer to patients in roughly half the time than the approximate 12 years it typically takes to bring a biologic to market,” said Torben Lund-Hansen, CTO, Head of Technical Operations, Y-mAbs. “Their end-to-end process development and GMP manufacturing services were key to achieving this milestone.”

The Martillac facility reportedly features two 2000-liter bioreactors in one manufacturing suite to increase capacity and flexibility.

Advertisement

Stories continue below